MARKET REPORT: Astrazeneca is boosted by vaccine trial optimism
Investors were given another shot of good news from Astrazeneca on the eve of its third-quarter figures. A definitive result from in-depth trials of its potential Covid-19 vaccine could be available by the end of this year, says the trial’s chief investigator Andrew Pollard. His comments come days after Britain’s health regulator, the Medicines and … Read more